{"id":"cimetra-1","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CimetrA-1 is developed by MGC Pharmaceuticals as a cannabis-derived or cannabinoid pharmaceutical candidate. It is designed to interact with cannabinoid receptors and the endocannabinoid system to reduce inflammation and provide therapeutic benefit in neurological or inflammatory conditions. The exact molecular mechanism and primary target remain proprietary, but the drug is positioned within the emerging cannabinoid therapeutics space.","oneSentence":"CimetrA-1 is a cannabinoid-based therapeutic that modulates endocannabinoid system signaling to produce anti-inflammatory and neuroprotective effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:54.363Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neurological or inflammatory conditions (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT05037162","phase":"PHASE2","title":"Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19","status":"COMPLETED","sponsor":"MGC Pharmaceuticals d.o.o","startDate":"2022-10-11","conditions":"Covid19, Corona Virus Infection","enrollment":240},{"nctId":"NCT04802382","phase":"PHASE3","title":"Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19","status":"UNKNOWN","sponsor":"MGC Pharmaceuticals d.o.o","startDate":"2021-06-11","conditions":"Corona Virus Infection, Covid19, SARS-CoV Infection","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CimetrA-1 drug administration"],"phase":"phase_3","status":"active","brandName":"CimetrA-1","genericName":"CimetrA-1","companyName":"MGC Pharmaceuticals d.o.o","companyId":"mgc-pharmaceuticals-d-o-o","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CimetrA-1 is a cannabinoid-based therapeutic that modulates endocannabinoid system signaling to produce anti-inflammatory and neuroprotective effects. Used for Neurological or inflammatory conditions (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}